Evaluation demonstrates stable ADAMTS13 and coagulation function in therapeutic plasma exchange for thrombotic thrombocytopenic purpura, suggesting safety in adjunct use.
Key Points
Stable ADAMTS13 activity was observed in liquid plasma during its shelf-life, enhancing therapeutic plasma exchange for thrombotic thrombocytopenic purpura.
The study found no significant differences in adverse outcomes like coagulopathy and mortality between patients using liquid plasma and those using thawed plasma alone.
Serial testing confirmed sustained coagulation function metrics across the studied duration, supporting the safety of combinational treatments.
These findings indicate liquid plasma could provide a viable alternative to thawed plasma, potentially reducing waste in clinical settings.